Indoleamine 2,3-Dioxygenase (Ido1) activity is increased in early chronic phase Chronic Myelogenous Leukemia (CML) and predicts molecular response to nilotinib therapy

S. Sopper, S. Mustjoki, S. Geisler, D. Fuchs, H. Hackl, Z. Trajanoski, A. Hochhaus, D. Wolf

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Original languageEnglish
JournalEuropean Journal of Immunology
Volume47
Pages (from-to)170-170
Number of pages1
ISSN0014-2980
Publication statusPublished - Dec 2017
Event47th Annual Meeting of the German-Society-for-Immunology (DGFI) - Erlangen, Germany
Duration: 12 Sep 201715 Sep 2017

Cite this

@article{63418f43bf1c4db9b0947906053e1e4d,
title = "Indoleamine 2,3-Dioxygenase (Ido1) activity is increased in early chronic phase Chronic Myelogenous Leukemia (CML) and predicts molecular response to nilotinib therapy",
author = "S. Sopper and S. Mustjoki and S. Geisler and D. Fuchs and H. Hackl and Z. Trajanoski and A. Hochhaus and D. Wolf",
year = "2017",
month = "12",
language = "English",
volume = "47",
pages = "170--170",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley",

}

Indoleamine 2,3-Dioxygenase (Ido1) activity is increased in early chronic phase Chronic Myelogenous Leukemia (CML) and predicts molecular response to nilotinib therapy. / Sopper, S.; Mustjoki, S.; Geisler, S.; Fuchs, D.; Hackl, H.; Trajanoski, Z.; Hochhaus, A.; Wolf, D.

In: European Journal of Immunology, Vol. 47, 12.2017, p. 170-170.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

TY - JOUR

T1 - Indoleamine 2,3-Dioxygenase (Ido1) activity is increased in early chronic phase Chronic Myelogenous Leukemia (CML) and predicts molecular response to nilotinib therapy

AU - Sopper, S.

AU - Mustjoki, S.

AU - Geisler, S.

AU - Fuchs, D.

AU - Hackl, H.

AU - Trajanoski, Z.

AU - Hochhaus, A.

AU - Wolf, D.

PY - 2017/12

Y1 - 2017/12

M3 - Meeting Abstract

VL - 47

SP - 170

EP - 170

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

ER -